BackProtagenic Therapeutics Overview

Protagenic Therapeutics Total Liabilities

Track Protagenic Therapeutics's total liabilities ($6.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$6.82M
623.81% YoYΔ $5.88M vs prior year quarter

Peer average

Loading

Protagenic Therapeutics Total Liabilities History

Loading

Protagenic Therapeutics vs. peers: Total Liabilities Comparison

Loading

Protagenic Therapeutics Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Protagenic Therapeutics (PTIX) FAQ

The latest total liabilities for PTIX is $6.8M as of December 2025. That compares with $940K in the prior-year period — up 623.8% year over year. Investors often review this figure alongside Protagenic Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, PTIX's total liabilities moved from $940K to $6.8M — a 623.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Protagenic Therapeutics's operating scale or balance-sheet position.

A total liabilities figure of $6.8M for PTIX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PTIX's total liabilities ($6.8M), review year-over-year change from $940K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Protagenic Therapeutics's total liabilities against similar Industrials names. You can also browse sector and industry screens on Stockcircle for a broader set of Industrials companies and their key multiples and fundamentals.